Elevance Health Reinstated at Inline by Evercore ISI: Is the Medicare Advantage Bounce Already Priced In?

Elevance Health (NYSE:ELV | ELV Price Prediction) stock surged this week after the Centers for Medicare & Medicaid Services finalized a 2.48% Medicare Advantage payment rate increase for 2027, coming in above the high end of the 1% to 2% improvement the market was expecting. Elevance Health shares are now up to $315. That’s meaningful, but Wall Street is asking: is the good news already priced in?

Evercore ISI thinks it might be. The firm reinstated coverage of Elevance Health on Wednesday at Inline with a $345 price target, a cautious stance signaling limited near-term upside after this week’s rally. Bank of America also weighed in on April 7, raising its price target to $405 from $385 while maintaining a Neutral rating, citing the same Medicare Advantage catalyst.

So, let’s look at what the numbers say about where Elevance Health stands heading into what management has flagged as a challenging year.

The Analyst’s Case

Evercore ISI’s Inline rating is a hold, suggesting Elevance Health stock is fairly valued near current levels after the Medicare Advantage bounce. The $345 price target sits only modestly above the current share price, suggesting the firm sees the near-term catalyst as largely absorbed. The sector-wide rally confirms the rate decision was a broad tailwind: UnitedHealth Group (NYSE:UNH) stock jumped 13.73% over the past week, and Humana (NYSE:HUM) shares gained 13.7%, suggesting ELV’s move was actually more modest than its peers.

Company Snapshot

Elevance Health generated $199.125 billion in revenue in FY 2025, up 12.62% year-over-year, with Medicare Advantage membership growing 7.9% year-over-year in Q4 2025. Carelon Services revenue climbed 47.1% year-over-year in Q4. However, the Health Benefits segment swung to a $200 million operating loss in Q4 2025 from a $207 million gain in Q4 2024, underscoring margin pressure in the current environment.

Why the Move Matters Now

The core challenge for Elevance Health in 2026 is an earnings trough that management has been transparent about. The company guided for adjusted diluted EPS of at least $25.50 in 2026, down from $30.29 in 2025, with the adjusted effective tax rate rising to 22% to 24% from 17.6%. The stock’s trailing P/E ratio of 12x looks cheap, yet forward earnings are declining and the benefit expense ratio hit 93.5% in Q4 2025, up 110 basis points year-over-year.

What It Means for Your Portfolio

CEO Gail K. Boudreaux reaffirmed the company’s long-term target to “return to at least 12% adjusted EPS growth in 2027,” and the CMS rate decision is a genuine positive step toward recovery. With approximately $6.7 billion in share repurchase authorization remaining and a dividend yield of 2.26%, there’s a reasonable income floor for patient investors.

Evercore ISI’s cautious reinstatement is a useful reality check. You should consider Elevance Health stock if you believe 2026 is a true trough and the 2027 recovery story is intact. Watch for whether the benefit expense ratio improves toward the 90.2% guidance target for FY 2026 as the clearest signal that the turnaround is on track.